Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...

Vyvgart (efgartigimod alfa-fcab) is a prescription drug that’s used to treat myasthenia gravis (MG). Vyvgart comes as a liquid solution that’s given as an intravenous (IV) infusion.

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

These drugs work by blocking FcRn and impairing ... its core portfolio with the help of collaborative partners. The molecule in Vyvgart originated from a collaboration with UT Southwestern Medical ...

Argenx (NASDAQ:ARGX) has received FDA approval for Vyvgart Hytrulo for the treatment of adults with chronic inflammatory demyelinating polyneuropathy, or CIDP. The Dutch biotech company said the ...

Updated results from the ADVANCE IV study of Vyvgart (efgartigimod alfa) showed that more than half of patients with ITP treated with Argenx' drug showed an improvement in platelet counts ...

argenx SE (NASDAQ:ARGX) reported Q4 2024 results and provided a pipeline update today, but without major surprises since the company provided Vyvgart net sales and a corporate update ahead of the ...

"In 2024, we significantly expanded our global patient reach with VYVGART, surpassing 10,000 patients across three indications,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.